Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults

Target Audience
The educational design of this activity addresses the needs of pulmonologists, allergists/immunologists, NPs and PAs, and other clinicians involved in the management of patients with moderate‐to‐severe asthma.

Program Overview
Patients with asthma and underlying comorbidities require personalized treatment to achieve asthma control. Children with asthma have an especially high burden of symptoms, and are at risk of impaired lung development if asthma control cannot be achieved. Many patients with asthma are candidates for biologic therapies, which can significantly improve the burden of disease.

Join a panel of pulmonology and allergy experts, who will discuss patient cases to illustrate disease and management aspect of asthma with comorbidities. Panelists will review the negative impact of uncontrolled moderate‐to‐severe asthma on airway remodeling and lung development in children. Panelists will also discuss conditions that occur frequently with asthma and their shared pathophysiology as a treatment target. Current evidence, including long‐term data and guideline recommendations for asthma treatment will be explored, along with strategies to develop personalized treatment plans for patients based on asthma phenotype, biomarkers, and comorbidities.

Learning Objectives
After completing this activity, the participant should be better able to:

Summarize the negative effects of comorbidities on the disease burden of moderate‐to‐severe asthma and on clinicians’ ability to achieve disease control
Explain the negative consequences of failure to achieve control of moderate‐to‐severe asthma on lung development in children
Apply current evidence and guidelines to identify appropriate biologic therapies for severe asthma based on phenotype, biomarkers, and comorbidities